WELLCOVORIN Drug Patent Profile
✉ Email this page to a colleague
When do Wellcovorin patents expire, and when can generic versions of Wellcovorin launch?
Wellcovorin is a drug marketed by Glaxosmithkline and is included in five NDAs.
The generic ingredient in WELLCOVORIN is leucovorin calcium. There are nine drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the leucovorin calcium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Wellcovorin
A generic version of WELLCOVORIN was approved as leucovorin calcium by HIKMA on September 14th, 1987.
Summary for WELLCOVORIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 63 |
Clinical Trials: | 96 |
Patent Applications: | 5,849 |
Formulation / Manufacturing: | see details |
DailyMed Link: | WELLCOVORIN at DailyMed |
Recent Clinical Trials for WELLCOVORIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Mayo Clinic | Phase 1 |
Jonsson Comprehensive Cancer Center | Phase 1/Phase 2 |
Arcus Biosciences, Inc. | Phase 1/Phase 2 |